2022-500758-41-00招募中1 期
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-201 IN AMYOTROPHIC LATERAL SCLEROSIS
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 35
- 试验地点
- 7
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Bryan Boggs
Scientific
Quralis Corp.
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
1 期
MT10109L in the Treatment of Glabellar LinesGlabellar LinesMedDRA version: 20.0Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858EUCTR2018-004384-31-BEAllergan Ltd.225
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by an Open Label Extension Phase in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivityeurogenic detrusor overactivity as a result of spinal cord injury, in patients with urinary incontinence, who have not been adequately managed with anticholinergic therapy.MedDRA version: 9.1Level: PTClassification code 10029279Term: Neurogenic bladderEUCTR2007-003407-12-GRAllergan Limited160
未知
3 期
A Multicenter, Double-Blind, Randomized, Placebo-Controlled PhaseIII Study to Evaluate the Efficacy and Safety of OVF in Opioid tolerant Patients With Cancer and Breakthrough Pain.JPRN-jRCT2080221194Taiho Pharmaceutical Co., Ltd.
进行中（未招募）
不适用
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-ResponseStudy to Evaluate the Safety and Efficacy of a Single Treatment of BOTOX®(Botulinum Toxin Type A) Purified Neurotoxin Complex Injected into the Prostatefor the Treatment of Lower Urinary Tract Symptoms in Patients due to BenignProstatic HyperplasiaPatients with lower urinary tract symptoms due to Benign Prostatic HyperplasiaMedDRA version: 9.1Level: LLTClassification code 10004446Term: Benign prostatic hyperplasiaEUCTR2005-004281-17-ATAllergan Inc.350
进行中（未招募）
1 期
A global study completed at hospitals in US, Europe & Asia using an investigational drug (Perampanel) to research its safety & effectiveness inpatients who are at least 2 years of age with Lennox-Gastaut SyndromeSeizures associated with Lennox-Gastaut Syndrome (LGS)MedDRA version: 20.1Level: PTClassification code 10048816Term: Lennox-Gastaut syndromeSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-002321-35-ITEISAI LIMITED142